274 related articles for article (PubMed ID: 25998099)
1. K356dup--an in-frame insertion in the BCR-ABL gene in an imatinib-resistant chronic myeloid leukemia.
Gniot M; Wasilewska EM; Lewandowski K
Int J Lab Hematol; 2012 Dec; 34(6):e3-6. PubMed ID: 25998099
[No Abstract] [Full Text] [Related]
2. Computational analysis of ABL kinase mutations allows predicting drug sensitivity against selective kinase inhibitors.
Kamasani S; Akula S; Sivan SK; Manga V; Duyster J; Vudem DR; Kancha RK
Tumour Biol; 2017 May; 39(5):1010428317701643. PubMed ID: 28475010
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of resistance to BCR-ABL and other kinase inhibitors.
Lamontanara AJ; Gencer EB; Kuzyk O; Hantschel O
Biochim Biophys Acta; 2013 Jul; 1834(7):1449-59. PubMed ID: 23277196
[TBL] [Abstract][Full Text] [Related]
4. New concepts for CML clonality.
Khorashad JS; Deininger MW; O'Hare T
Oncotarget; 2013 Jan; 4(1):7-8. PubMed ID: 23448894
[No Abstract] [Full Text] [Related]
5. Monitoring minimal residual disease and controlling drug resistance in chronic myeloid leukaemia patients in treatment with imatinib as a guide to clinical management.
Martinelli G; Iacobucci I; Soverini S; Cilloni D; Saglio G; Pane F; Baccarani M
Hematol Oncol; 2006 Dec; 24(4):196-204. PubMed ID: 16988930
[TBL] [Abstract][Full Text] [Related]
6. Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation.
Pemovska T; Johnson E; Kontro M; Repasky GA; Chen J; Wells P; Cronin CN; McTigue M; Kallioniemi O; Porkka K; Murray BW; Wennerberg K
Nature; 2015 Mar; 519(7541):102-5. PubMed ID: 25686603
[TBL] [Abstract][Full Text] [Related]
7. Characteristics of the TCR Vβ repertoire in imatinib-resistant chronic myeloid leukemia patients with ABL mutations.
Xu L; Lu Y; Lai J; Yu W; Zhang Y; Jin Z; Xu Y; Chen J; Zha X; Chen S; Yang L; Li Y
Sci China Life Sci; 2015 Dec; 58(12):1276-81. PubMed ID: 26423566
[TBL] [Abstract][Full Text] [Related]
8. Recent advances in Bcr-Abl tyrosine kinase inhibitors for overriding T315I mutation.
Liu J; Zhang Y; Huang H; Lei X; Tang G; Cao X; Peng J
Chem Biol Drug Des; 2021 Mar; 97(3):649-664. PubMed ID: 33034143
[TBL] [Abstract][Full Text] [Related]
9. Presence of a new BCR-ABL kinase domain mutation, C330G in an imatinib naive patient with chronic myeloid leukemia: very low prevalence of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia from eastern India.
Kuila N; Dash N; Sahoo DP; Pattnayak NC; Biswas G; Chakraborty S
Leuk Lymphoma; 2009 Apr; 50(4):663-6. PubMed ID: 19373669
[No Abstract] [Full Text] [Related]
10. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
Ferri C; Bianchini M; Bengió R; Larripa I
Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
[TBL] [Abstract][Full Text] [Related]
11. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.
Mahon FX; Réa D; Guilhot J; Guilhot F; Huguet F; Nicolini F; Legros L; Charbonnier A; Guerci A; Varet B; Etienne G; Reiffers J; Rousselot P;
Lancet Oncol; 2010 Nov; 11(11):1029-35. PubMed ID: 20965785
[TBL] [Abstract][Full Text] [Related]
12. Concomitant AID Expression and BCL7A Loss Associates With Accelerated Phase Progression and Imatinib Resistance in Chronic Myeloid Leukemia.
Yu N; Shin S; Choi JR; Kim Y; Lee KA
Ann Lab Med; 2017 Mar; 37(2):177-179. PubMed ID: 28029010
[No Abstract] [Full Text] [Related]
13. Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors.
Redaelli S; Mologni L; Rostagno R; Piazza R; Magistroni V; Ceccon M; Viltadi M; Flynn D; Gambacorti-Passerini C
Am J Hematol; 2012 Nov; 87(11):E125-8. PubMed ID: 23044928
[TBL] [Abstract][Full Text] [Related]
14. Abl tyrosine kinase inhibitors for overriding Bcr-Abl/T315I: from the second to third generation.
Tanaka R; Kimura S
Expert Rev Anticancer Ther; 2008 Sep; 8(9):1387-98. PubMed ID: 18759691
[TBL] [Abstract][Full Text] [Related]
15. Experimental and integrative analyses identify an ETS1 network downstream of BCR-ABL in chronic myeloid leukemia (CML).
Desterke C; Voldoire M; Bonnet ML; Sorel N; Pagliaro S; Rahban H; Bennaceur-Griscelli A; Cayssials E; Chomel JC; Turhan AG
Exp Hematol; 2018 Aug; 64():71-83.e8. PubMed ID: 29733872
[TBL] [Abstract][Full Text] [Related]
16. HS-438, a new inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.
Yun SM; Jung KH; Kim SJ; Fang Z; Son MK; Yan HH; Lee H; Kim J; Shin S; Hong S; Hong SS
Cancer Lett; 2014 Jun; 348(1-2):50-60. PubMed ID: 24657654
[TBL] [Abstract][Full Text] [Related]
17. Implication of the Autologous Immune System in BCR-ABL Transcript Variations in Chronic Myelogenous Leukemia Patients Treated with Imatinib.
Clapp GD; Lepoutre T; El Cheikh R; Bernard S; Ruby J; Labussière-Wallet H; Nicolini FE; Levy D
Cancer Res; 2015 Oct; 75(19):4053-62. PubMed ID: 26359456
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of resistance to BCR-ABL TKIs and the therapeutic strategies: A review.
Yang K; Fu LW
Crit Rev Oncol Hematol; 2015 Mar; 93(3):277-92. PubMed ID: 25500000
[TBL] [Abstract][Full Text] [Related]
19. ABL1-Directed Inhibitors for CML: Efficacy, Resistance and Future Perspectives.
Massimino M; Stella S; Tirrò E; Pennisi MS; Vitale SR; Puma A; Romano C; DI Gregorio S; Tomarchio C; DI Raimondo F; Manzella L
Anticancer Res; 2020 May; 40(5):2457-2465. PubMed ID: 32366389
[TBL] [Abstract][Full Text] [Related]
20. The effectiveness of interferon-α combined with imatinib in patient with chronic myeloid leukemia harboring T315I BCR-ABL1 mutation.
Zhang H; Liang Z; Hu Y; Wang X; Wang B; Huang H
Leuk Lymphoma; 2018 Dec; 59(12):3018-3019. PubMed ID: 29616854
[No Abstract] [Full Text] [Related]
[Next] [New Search]